

A prospective, randomised double-blind crossover study of strontium-89 in pain palliation in patients with advanced bone

European Journal of Cancer & Clinical Oncology
27, 954-958

DOI: [10.1016/0277-5379\(91\)90257-e](https://doi.org/10.1016/0277-5379(91)90257-e)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Radionuclide therapy revisited. European Journal of Nuclear Medicine and Molecular Imaging, 1991, 18, 408-431.	2.2	120
2	⁸⁹ Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes. British Journal of Cancer, 1992, 66, 177-180.	2.9	34
3	Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Clinical Oncology, 1992, 4, 160-164.	0.6	29
4	Strontium-89-precursor targeted therapy for pain relief of blastic metastatic disease. Cancer, 1993, 72, 3433-3435.	2.0	36
5	New bisphosphonates in the treatment of bone metastases. Cancer, 1993, 72, 3443-3452.	2.0	58
6	Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges for future research. Supportive Care in Cancer, 1993, 1, 26-33.	1.0	12
7	Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. International Journal of Radiation Oncology Biology Physics, 1993, 25, 805-813.	0.4	507
8	Pain palliation and nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 1993, 20, 1-3.	2.2	5
9	Targeted radionuclide therapy for bone metastases. European Journal of Nuclear Medicine and Molecular Imaging, 1993, 20, 66-74.	2.2	82
10	Osteoclast inhibition for the treatment of bone metastases. Cancer Treatment Reviews, 1993, 19, 79-103.	3.4	62
11	An overview of current clinical experience with strontium-89 (Metastron®). Prostate, 1994, 25, 23-26.	1.2	13
12	Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. International Journal of Radiation Oncology Biology Physics, 1994, 30, 1187-1194.	0.4	58
13	Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: single institution experience. British Journal of Urology, 1994, 74, 345-351.	0.1	38
14	The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology, 1994, 44, 481-485.	0.5	21
15	Strontium-89 in metastatic prostate cancer. Urology, 1994, 44, 75-80.	0.5	2
16	A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiotherapy and Oncology, 1994, 31, 33-40.	0.3	325
17	Radionuclide therapy in oncology. Cancer Treatment Reviews, 1994, 20, 51-71.	3.4	13
18	Opioid pharmacotherapy in the management of cancer pain. A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer, 1995, 76, 1283-1293.	2.0	150

#	ARTICLE	IF	CITATIONS
19	The pathophysiology and management of spine metastasis from lung cancer. <i>Journal of Neuro-Oncology</i> , 1995, 23, 109-120.	1.4	9
20	Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995, 22, 1101-1104.	2.2	25
21	Strontium 89 Therapy for the Palliation of Pain Due to Osseous Metastases. <i>JAMA - Journal of the American Medical Association</i> , 1995, 274, 420.	3.8	138
22	Cancer therapy using bone-seeking isotopes. <i>Physics in Medicine and Biology</i> , 1996, 41, 2027-2042.	1.6	60
24	Skeletal Metastases. <i>Acta OncolÃ³gica</i> , 1996, 35, 125-136.	0.8	6
25	Pain palliation with strontium-89 in children with metastatic disease. , 1996, 26, 393-396.		11
26	Postoperative irradiation treatment and bioresorbable implants in orthopaedic surgery: an experimental in vitro study. <i>Biomaterials</i> , 1996, 17, 1149-1153.	5.7	6
27	The current status of targeted radiotherapy in clinical practice. <i>Physics in Medicine and Biology</i> , 1996, 41, 1895-1903.	1.6	17
28	Radioisotopes in the Treatment of Bone Metastases. <i>Annals of Medicine</i> , 1997, 29, 31-35.	1.5	36
29	Radionuclide Developments. <i>British Journal of Radiology</i> , 1997, 70, S133-S144.	1.0	3
30	Systemic Radionuclide Palliative Therapy for Metastatic Carcinoma with Strontium 89. <i>Journal of Pharmacy Practice</i> , 1997, 10, 352-360.	0.5	0
31	Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. <i>Radiotherapy and Oncology</i> , 1997, 45, 109-116.	0.3	263
32	The placebo effect. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1433-1440.	3.3	13
33	Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1210-1214.	3.3	84
34	Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 590-595.	2.2	47
35	Unsealed source therapy of painful bone metastases: An update. <i>Seminars in Nuclear Medicine</i> , 1997, 27, 165-182.	2.5	65
36	Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma. <i>Nuclear Medicine and Biology</i> , 1997, 24, 319-325.	0.3	20
37	Pain control in patients with cancer. <i>European Journal of Cancer</i> , 1997, 33, S55-S62.	1.3	6

#	ARTICLE	IF	CITATIONS
38	Experience with 89-Strontium Treatment of Painful Osseous Metastases from Breast Cancer. <i>Tumori</i> , 1997, 83, 558-559.	0.6	1
39	Radiotherapy for painful bone metastases: A systematic review. <i>Clinical Oncology</i> , 1997, 9, 150-154.	0.6	73
40	Hormone resistance in prostate cancer. <i>Cancer and Metastasis Reviews</i> , 1998, 17, 373-381.	2.7	71
41	Radiotherapeutic Management of Osseous Metastases: A Survey of Current Patterns of Care. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 40, 915-921.	0.4	94
42	Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts. <i>Ca-A Cancer Journal for Clinicians</i> , 1998, 48, 361-374.	157.7	17
43	The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1362-1367.	3.3	66
44	Update Palliative Therapy with Bone Seeking Radiopharmaceuticals. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1998, 13, 413-426.	0.7	22
45	Management of Pain and Spinal Cord Compression in Patients with Advanced Cancer. <i>Annals of Internal Medicine</i> , 1999, 131, 37.	2.0	42
46	Evaluation of Efficacy and Toxicity of Treatment Using Rhenium-186 HEDP in Metastatic Bone Disease. <i>Medical Principles and Practice</i> , 1999, 8, 196-200.	1.1	3
47	Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. <i>British Journal of Cancer</i> , 1999, 79, 538-544.	2.9	68
49	TECHNICAL ADVANCES IN RADIOTHERAPY OF HEAD AND NECK TUMORS. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 811-823.	0.9	2
50	Radiotherapy for the palliation of painful bone metastases. , 1999, , CD001793.		76
51	LOCAL AND SYSTEMIC RADIATION FOR PALLIATION OF METASTATIC DISEASE. <i>Urologic Clinics of North America</i> , 1999, 26, 391-402.	0.8	27
52	CANCER PAIN MANAGEMENT. <i>Medical Clinics of North America</i> , 1999, 83, 711-736.	1.1	28
53	Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases. <i>Nuclear Medicine and Biology</i> , 1999, 26, 973-976.	0.3	39
54	Chapter 12 Current management of hormone-refractory prostate cancer. <i>Advances in Oncobiology</i> , 1999, , 235-255.	0.0	0
55	Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate. , 2000, 88, 620-624.		34
56	Use of radionuclides for the palliation of bone metastases. <i>Seminars in Radiation Oncology</i> , 2000, 10, 103-114.	1.0	82

#	ARTICLE	IF	CITATIONS
57	The management of cancer pain. <i>Ca-A Cancer Journal for Clinicians</i> , 2000, 50, 70-116.	157.7	110
58	Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1487-1493.	2.2	107
59	Special Techniques in Palliative Radiation Oncology. <i>Journal of Palliative Medicine</i> , 2000, 3, 75-83.	0.6	5
60	Management of Bone Metastases. <i>Oncologist</i> , 2000, 5, 463-470.	1.9	144
61	ADVANCES IN PAIN MANAGEMENT FOR OLDER ADULT PATIENTS. <i>Clinics in Geriatric Medicine</i> , 2000, 16, 269-311.	1.0	33
62	Radionuclide therapy with bone-seeking compounds: Monte Carlo calculations of dose-volume histograms for bone marrow in trabecular bone. <i>Physics in Medicine and Biology</i> , 2001, 46, 1149-1161.	1.6	31
63	Metastatic bone disease: clinical features, pathophysiology and treatment strategies. <i>Cancer Treatment Reviews</i> , 2001, 27, 165-176.	3.4	1,651
64	Recent advances in radionuclide therapy. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 330-341.	2.5	85
65	Present status of palliative radiotherapy. <i>European Journal of Cancer</i> , 2001, 37, 279-288.	1.3	6
66	Pain assessment and management. <i>Primary Care - Clinics in Office Practice</i> , 2001, 28, 269-297.	0.7	5
67	Bone pain. , 2001, , 515-532.		0
68	The Silent Epidemic: Tobacco and the Evolution of Lung Cancer and Its Treatment. <i>Cancer Investigation</i> , 2001, 19, 739-751.	0.6	9
69	Serum chromogranin-A in advanced prostate cancer. <i>BJU International</i> , 2001, 88, 790-796.	1.3	36
70	Treatment with radioactive 89strontium for patients with bone metastases from prostate cancer. <i>BJU International</i> , 2001, 86, 929-934.	1.3	13
71	Strontium-89 treatment for prostate cancer bone metastases: Does a prostate-specific antigen response predict for improved survival?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2001, 45, 39-42.	0.6	31
72	Radiotherapy for Bone Metastases. <i>Clinical Oncology</i> , 2001, 13, 88-90.	0.6	19
73	Predictors of Response to Strontium-89 (Metastron®) in Skeletal Metastases from Prostate Cancer: Report of a Single Centre's 10-Year Experience. <i>Clinical Oncology</i> , 2001, 13, 219-227.	0.6	15
74	Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. <i>British Journal of Cancer</i> , 2001, 84, 297-302.	2.9	76

#	ARTICLE	IF	CITATIONS
76	A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. <i>Cancer</i> , 2002, 94, 1654-1660.	2.0	61
77	A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector: application to a study of ⁸⁹ SrCl ₂ and ¹⁵³ Sm-EDTMP in a dog with spontaneous osteosarcoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 191-197.	3.3	8
78	Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 494-498.	3.3	39
79	High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. <i>British Journal of Cancer</i> , 2002, 86, 1715-1720.	2.9	57
80	Future directions for unsealed source radionuclide therapy for bone metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1271-1275.	3.3	13
81	Radioisotopic treatment of bone pain from metastatic prostate cancer. <i>Current Oncology Reports</i> , 2003, 5, 258-262.	1.8	12
82	Radiotherapeutic approaches to metastatic disease. <i>World Journal of Urology</i> , 2003, 21, 229-242.	1.2	8
83	Strontium-89 Chloride versus Palliative Local Field Radiotherapy in Patients with Hormonal Escaped Prostate Cancer: A Phase III Study of the European Organisation for Research and Treatment of Cancer Genitourinary Group. <i>European Urology</i> , 2003, 44, 519-526.	0.9	121
84	The management of hormone-relapsed prostate cancer. <i>BJU International</i> , 2003, 92, 860-868.	1.3	17
86	Complexation of ¹⁸⁸ Re-phosphonates: in vitro and in vivo studies. <i>Radiochimica Acta</i> , 2003, 91, 607-612.	0.5	6
87	Bone as an Effect Compartment. <i>Clinical Pharmacokinetics</i> , 2003, 42, 863-881.	1.6	50
89	Studies on the Synthesis and Biological Properties of Non-Carrier-Added [¹²⁵ I and ¹³¹ I]-Labeled Arylalkylidenebisphosphonates: A Potent Bone-Seekers for Diagnosis and Therapy of Malignant Osseous Lesions. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3021-3032.	2.9	22
90	Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate. <i>Journal of Clinical Oncology</i> , 2003, 21, 2869-2875.	0.8	157
91	Clinical Approaches to Osseous Metastases in Prostate Cancer. <i>Oncologist</i> , 2003, 8, 161-173.	1.9	32
92	Placebo Effects in Oncology. <i>Journal of the National Cancer Institute</i> , 2003, 95, 19-29.	3.0	100
93	Radioisotopes for metastatic bone pain. , 2003, , CD003347.		46
94	Bone-Seeking Radiopharmaceuticals to Palliate Painful Bone Metastases. , 2003, , .		0
95	Radiopharmaceuticals for palliation of painful osseous metastases. <i>American Journal of Hospice and Palliative Medicine</i> , 2004, 21, 303-313.	0.8	15

#	ARTICLE	IF	CITATIONS
96	Adjuvant Analgesics in Cancer Pain Management. <i>Oncologist</i> , 2004, 9, 571-591.	1.9	213
97	Pain and Its Management in Patients with Cancer. <i>Cancer Investigation</i> , 2004, 22, 799-809.	0.6	3
98	Managing metastatic bone disease: Three case studies. <i>Seminars in Oncology</i> , 2004, 31, 83-86.	0.8	17
99	Targeting osseous metastases: Rationale and development of radioimmunotherapy for prostate cancer. <i>Current Oncology Reports</i> , 2004, 6, 222-229.	1.8	0
100	Establishing Schedules for Repeated Doses of Strontium and for Concurrent Chemotherapy in Hormone-Resistant Patients With Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 138-142.	0.6	2
101	Management of bone metastases in cancer: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 365-378.	2.0	203
102	Palliation of Bone Pain in Prostate Cancer Using Chemotherapy and Strontium-89. A Randomized Phase II Study. <i>Journal of Pain and Symptom Management</i> , 2005, 29, 352-357.	0.6	34
103	Cancer of the prostate. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 379-396.	2.0	89
104	Targeting osseous metastases: rationale and development of radioimmunotherapy for prostate cancer. <i>Current Urology Reports</i> , 2005, 6, 163-170.	1.0	0
105	Radioisotopes for the palliation of metastatic bone cancer: a systematic review. <i>Lancet Oncology</i> , The, 2005, 6, 392-400.	5.1	334
106	Radiopharmaceuticals for the palliation of painful bone metastases—a systematic review. <i>Radiotherapy and Oncology</i> , 2005, 75, 258.E1-258.E13.	0.3	148
107	Radiotherapy in cancer pain management. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 87-96.	2.2	0
108	Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. <i>Bone</i> , 2006, 39, 35-41.	1.4	68
109	Metastatic Cancer to Bone. , 2006, , 1664-1688.		2
110	A phase 2 study of high-activity ¹⁸⁶ Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1055-1061.	3.3	24
111	Management of the Spectrum of Hormone Refractory Prostate Cancer. <i>European Urology</i> , 2006, 50, 428-439.	0.9	43
112	High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α -Emitter ²²³ Ra: Adjuvant or Alternative to Conventional Modalities?. <i>Clinical Cancer Research</i> , 2006, 12, 6250s-6257s.	3.2	303
113	The role of electron-emitting radiopharmaceuticals in the palliative treatment of metastatic bone pain and for radiosynovectomy: applications of conversion electron emitter Tin-117m. <i>Brazilian Archives of Biology and Technology</i> , 2007, 50, 49-62.	0.5	14

#	ARTICLE	IF	CITATIONS
114	Radionuclide Treatment in Metastasized Prostate Cancer. EAU-EBU Update Series, 2007, 5, 113-125.	0.7	4
115	Traitement antalgique des métastases osseuses douloureuses par radiothérapie interne vectorisée. Médecine Nucleaire, 2007, 31, 262-270.	0.2	3
116	Radium-223 for men with hormone-refractory prostate cancer and bone metastases. Lancet Oncology, The, 2007, 8, 564-565.	5.1	7
117	Metastasis of Prostate Cancer. Cancer Metastasis - Biology and Treatment, 2007, , .	0.1	4
118	Radionuclide Therapy of Bone Metastases. , 2007, , 433-442.		1
119	Strategies for the Implementation of Chemotherapy and Radiotherapy. , 2008, , 309-335.		0
120	Radiopharmaceutical therapy of bone metastases with ⁸⁹ SrCl ₂ , ¹⁸⁶ Re-HEDP and ¹⁵³ Sm-EDTMP: a dosimetric study using Monte Carlo simulation. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1031-1038.	3.3	16
121	Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer and Metastasis Reviews, 2007, 25, 669-675.	2.7	41
122	Osteotropic radiopharmaceuticals based on phosphonic acids for the treatment of bone metastases in humans (review). Pharmaceutical Chemistry Journal, 2008, 42, 233.	0.3	5
123	Current and future treatments of bone metastases. Expert Opinion on Emerging Drugs, 2008, 13, 609-627.	1.0	14
125	Hypocalcemia Associated with Strontium-89 Administration in a Patient with Diffuse Bone Metastases from Neuroendocrine Carcinoma. Journal of Pain and Symptom Management, 2009, 37, 923-929.	0.6	3
126	Radionuclide Therapy. Cancer Metastasis - Biology and Treatment, 2009, , 321-341.	0.1	2
127	¹⁸⁸ Re(CO) ₃ -Dipicolylamine-Alendronate: A New Bisphosphonate Conjugate for the Radiotherapy of Bone Metastases. Bioconjugate Chemistry, 2010, 21, 811-815.	1.8	56
129	Bone-targeted therapy in metastatic prostate cancer: osteoclast inhibitors and bone-seeking radiopharmaceuticals. Drug Discovery Today: Therapeutic Strategies, 2010, 7, 23-29.	0.5	2
130	Radioisotopes for metastatic bone pain. , 2011, , CD003347.		33
131	Bone Seeking Radiopharmaceuticals for Metastatic Bone Pain. , 2011, , .		0
132	New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety. European Urology, 2011, 60, 279-290.	0.9	130
133	Successful Control of Intractable Hypoglycemia Using Radiopharmaceutical Therapy with Strontium-89 in a Case with Malignant Insulinoma and Bone Metastases. Japanese Journal of Clinical Oncology, 2012, 42, 640-645.	0.6	4

#	ARTICLE	IF	CITATIONS
134	Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment. <i>Prostate Cancer</i> , 2012, 2012, 1-11.	0.4	79
135	Quality of Life with Advanced Metastatic Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 505-515.	0.8	23
136	Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 583-591.	0.8	5
137	Current and emerging treatments in the management of castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 951-964.	1.1	25
138	Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. <i>Cancer Letters</i> , 2012, 323, 135-146.	3.2	88
139	Radionuclide treatment of painful bone metastases in patients with breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2012, 38, 164-171.	3.4	30
140	Radiopharmaceuticals for Bone Metastasis Therapy and Beyond: A Voyage from the Past to the Present and a Look to the Future. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 535-551.	0.7	17
141	Rhenium-188 Generator-Based Radiopharmaceuticals for Therapy. <i>Medical Radiology</i> , 2012, , 51-81.	0.0	5
142	Management of Pain in the Elderly at the End of Life. <i>Drugs and Aging</i> , 2012, 29, 285-305.	1.3	34
143	Optimal Management of Recurrent Prostate Cancer in Older Patients. <i>Drugs and Aging</i> , 2012, 29, 871-883.	1.3	8
144	Therapeutic Options for Advanced Prostate Cancer: 2011 Update. <i>Current Urology Reports</i> , 2012, 13, 170-178.	1.0	13
145	Effective use of strontium-89 in osseous metastases. <i>Annals of Nuclear Medicine</i> , 2012, 26, 197-206.	1.2	19
146	Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. <i>Inflammopharmacology</i> , 2013, 21, 339-363.	1.9	38
147	Targeted radio-nuclide therapy of skeletal metastases. <i>Cancer Treatment Reviews</i> , 2013, 39, 18-26.	3.4	50
148	Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. <i>Lancet Oncology</i> , The, 2013, 14, e524-e534.	5.1	42
149	Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2013, 15, 342-349.	0.8	27
150	Castrate-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 201-207.	0.9	6
151	Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 252-260.	1.1	35

#	ARTICLE	IF	CITATIONS
152	Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure. <i>Journal of Oncology Practice</i> , 2013, 9, 223-229.	2.5	29
153	Bone Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0,784314,rgBT /O</i>	1.0	27
154	Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms. <i>Prostate Cancer</i> , 2013, 2013, 1-10.	0.4	33
155	Radiotherapy for the palliation of painful bone metastases. <i>The Cochrane Library</i> , 2019, 2019, CD001793.	1.5	8
156	Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. <i>Cancer Management and Research</i> , 2013, 5, 1.	0.9	101
157	Bone Targeted Therapies for Bone Metastasis in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2013, 2, 176-187.	1.0	5
158	Novel Therapeutic Settings in the Treatment of Castration- Resistant Prostate Cancer. , 2013, , .		0
159	Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 651.	0.9	6
160	Radium-223 in metastatic castration resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 348.	0.8	12
161	Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2513-2524.	0.9	1
162	Minimally Invasive Local Treatments for Bone and Pulmonary Metastases. <i>Minimally Invasive Surgery</i> , 2014, 2014, 1-9.	0.1	5
163	Bone-Targeting Radiopharmaceuticals for the Treatment of Bone-Metastatic Castration-Resistant Prostate Cancer: Exploring the Implications of New Data. <i>Oncologist</i> , 2014, 19, 1012-1018.	1.9	14
164	How Are Palliative Care Cancer Populations Characterized in Randomized Controlled Trials? A Literature Review. <i>Journal of Pain and Symptom Management</i> , 2014, 47, 906-914.e17.	0.6	16
166	Radioisotopes reborn: radium-223 and its role in the management of prostate cancer. <i>Trends in Urology & Men's Health</i> , 2015, 6, 40-42.	0.2	0
167	Pharmacological Management of Cancer-Related Pain. <i>Cancer Control</i> , 2015, 22, 412-425.	0.7	43
168	Radium-223 for the treatment of castration-resistant prostate cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 1103.	1.0	10
169	Radium 223: How Can We Optimize This New Tool for Metastatic Castration-Resistant Prostate Cancer?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e270-e273.	1.8	2
170	Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5291.	2.0	8

#	ARTICLE	IF	CITATIONS
171	Targeting bone metastases in prostate cancer: improving clinical outcome. <i>Nature Reviews Urology</i> , 2015, 12, 340-356.	1.9	87
172	Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis. <i>Molecular and Clinical Oncology</i> , 2015, 3, 257-263.	0.4	13
173	The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer. <i>Therapeutic Advances in Urology</i> , 2015, 7, 135-145.	0.9	13
174	Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer. <i>Medicinal Research Reviews</i> , 2015, 35, 554-585.	5.0	32
175	Bone-targeted agents in the treatment of lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 219-228.	1.4	18
176	Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer going beyond PSA and imaging, a systematic literature review. <i>Annals of Oncology</i> , 2015, 26, 2221-2247.	0.6	10
177	Targeted Therapy for Metastatic Prostate Cancer with Radionuclides. , 2016, , .		5
178	SEOM Clinical Guideline for bone metastases from solid tumours (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1243-1253.	1.2	34
179	Therapeutic Radiopharmaceuticals for Bone Pain Palliation. , 2016, , 225-252.		2
180	Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Current Oncology Reports</i> , 2016, 18, 14.	1.8	39
181	Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. <i>European Urology</i> , 2016, 70, 416-426.	0.9	51
182	Prostate Cancer Metastasis. , 2017, , 33-59.		2
183	Radioisotopes for metastatic bone pain. <i>The Cochrane Library</i> , 2017, 3, CD003347.	1.5	4
184	Optimal usage of radium-223 in metastatic castration-resistant prostate cancer. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 825-836.	0.8	16
185	EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 846-859.	3.3	51
186	Pain Management in Metastatic Bone Disease: A Literature Review. <i>Cureus</i> , 2018, 10, e3286.	0.2	36
187	Un paso adelante en el tratamiento radiometabólico de las metástasis óseas con 223Ra. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 271-272.	0.0	0
188	Radionuclide Therapy for Bone Metastases. <i>PET Clinics</i> , 2018, 13, 491-503.	1.5	16

#	ARTICLE	IF	CITATIONS
190	The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 108-116.	2.0	17
191	Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases. <i>International Journal of Clinical Oncology</i> , 2019, 24, 557-566.	1.0	10
192	A comparative evaluation of calix[4]arene-1,3-crown-6 as a ligand for selected divalent cations of radiopharmaceutical interest. <i>RSC Advances</i> , 2019, 9, 32357-32366.	1.7	21
193	Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes. <i>JAMA Oncology</i> , 2020, 6, 206.	3.4	22
194	Spine and Non-spine Bone Metastases – Current Controversies and Future Direction. <i>Clinical Oncology</i> , 2020, 32, 728-744.	0.6	10
195	Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 485-489.	0.7	2
196	REVIEW ABOUT RADIOPHARMACEUTICALS: PREPARATION, RADIOACTIVITY, AND APPLICATIONS. <i>International Journal of Applied Pharmaceutics</i> , 2020, , 8-15.	0.3	5
197	<p></p>Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2127-2140.	0.9	12
198	Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy. <i>Seminars in Ultrasound, CT and MRI</i> , 2021, 42, 164-183.	0.7	0
199	Palliative Care and Cancer Pain. , 2021, , 91-111.		1
201	Current Concepts in the Treatment of Cancer of the Prostate. , 1996, , 379-394.		1
202	Cancer Pain in the Elderly. , 1997, , 267-307.		7
203	Therapeutic Nuclear Medicine in the UK. , 2016, , 121-128.		2
204	Pain from Metastatic Bone Tumors. , 1999, , 245-260.		1
205	Strontium-89 Chloride (Metastron) for Palliative Treatment of Bony Metastases: The University of Minnesota Experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 102-107.	0.6	40
206	Strontium-89 Therapy and Imaging With Bremsstrahlung in Bone Metastases. <i>Clinical Nuclear Medicine</i> , 1997, 22, 605-609.	0.7	27
207	Disseminated Intravascular Coagulation in a Patient Treated With Strontium-89 for Metastatic Carcinoma of the Prostate. <i>Clinical Nuclear Medicine</i> , 1999, 24, 852.	0.7	25
208	Bone-seeking therapeutic radiopharmaceuticals. <i>Brazilian Archives of Biology and Technology</i> , 2002, 45, 45-55.	0.5	11

#	ARTICLE	IF	CITATIONS
209	Current Concepts Review - Treatment of Metastatic Adenocarcinoma of the Pelvis and the Extremities*. Journal of Bone and Joint Surgery - Series A, 1997, 79, 917-32.	1.4	64
210	Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions. Current Medicinal Chemistry, 2020, 27, 3187-3249.	1.2	12
211	The diagnosis, management, treatment and costs of prostate cancer in England and Wales.. Health Technology Assessment, 1997, 1, .	1.3	56
212	Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technology Assessment, 2013, 17, 1-386.	1.3	32
213	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment, 2016, 20, 1-288.	1.3	29
214	Palliation of Bone Pain from Bone Metastasis by Strontium-89. Radioisotopes, 2008, 57, 739-752.	0.1	3
215	Future perspectives of prostate cancer therapy. Translational Andrology and Urology, 2012, 1, 19-32.	0.6	18
216	Novel non-AR therapeutic targets in castrate resistant prostate cancer. Translational Andrology and Urology, 2013, 2, 265-77.	0.6	4
217	Discrepancy between clinical symptoms and Tc-99m MDP bone scan findings before and after strontium-89 therapy for metastatic bone pain of prostate carcinoma. Clinical Nuclear Medicine, 2001, 26, 167-169.	0.7	0
218	Vertebral metastases of prostate cancer. , 2002, , 117-121.		0
219	Bone-Targeted Therapy for Prostate Cancer. , 2004, , 589-606.		1
220	Radiation Therapy in the Management of Cancer Pain. , 2007, , 328-336.		0
221	Radiopharmaceuticals. , 2010, , 255-266.		1
223	Beta-Emitting Radiopharmaceuticals and Bone Metastasis. , 2012, , 413-418.		0
224	Management of Bone Metastases. , 2013, , 1055-1063.		0
225	High-Intensity Focused Ultrasound Treatment for Bone Metastases. , 2013, , 653-663.		0
226	Castration-Resistant Prostate Cancer (mCRPC): Shifting from Palliation to Improving Survival. Journal of Nuclear Medicine & Radiation Therapy, 2014, 06, .	0.2	0
227	Strategies Addressing Quality of Life: Management of Patient-Reported Outcomes and Symptoms. Current Clinical Urology, 2014, , 307-320.	0.0	0

#	ARTICLE	IF	CITATIONS
228	Kemikteki metastatik t ₄ m ₄ rler. T ₄ rk Ortopedi Ve Travmatoloji Birliđi Derneđi, 2014, 13, .	0.0	1
229	Schmerztherapie beim Prostatakarzinom. , 1993, , 107-128.		0
230	Bew ^h rtes und Zuk ⁴ ftiges in der Tumorschmerztherapie. , 1994, , 1-16.		0
231	Systemic Therapy for Carcinoma of the Prostate. Medical Radiology, 1996, , 319-326.	0.0	0
232	Verhalten biodegradierbarer Polymerimplantate bei postoperativer Nachbestrahlung. Hefte Zur Zeitschrift Der Unfallchirurg, 1998, , 89-95.	0.0	0
233	Non-Curative Radiotherapy for Bone Metastases. Focus on Cancer, 1998, , 113-127.	0.1	0
234	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2015, 17, 936.	0.8	1
235	A History of Nuclear Medicine in the UK. , 2016, , 9-18.		0
236	Targeted Radionuclide Therapy for Bone Metastasis. , 2016, , 1-29.		0
237	Bone-Seeking Radionuclide for Therapy. , 2017, , 193-207.		0
238	Targeted Radionuclide Therapy for Bone Metastasis. , 2017, , 1307-1335.		0
239	Skeletal Complications in Patients with CRPC. , 2018, , 327-338.		0
240	Co-Targeting Therapeutics for Hormone Refractory Prostate Cancer. , 2007, , 463-473.		0
241	M ^o tastases vert ^o brales des cancers prostatiques. , 2007, , 179-184.		0
242	Radiopharmaceuticals for Prostate Cancer. , 2021, , 119-132.		0
243	Prostate cancer: 10. Palliative care. Cmaj, 1999, 160, 365-71.	0.9	9
244	Emerging Therapeutic for the Treatment of Skeletal-related Events Associated With Metastatic Castrate-resistant Prostate Cancer. Reviews in Urology, 2014, 16, 10-20.	0.9	7
245	Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clinical Advances in Hematology and Oncology, 2010, 8, 341-51.	0.3	11

#	ARTICLE	IF	CITATIONS
248	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	40
249	A Primer on Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	3
250	Targeted Radionuclide Therapy for Bone Metastasis. , 2022, , 1481-1513.		0
251	Team Approach: Management of Pathologic Fractures. JBJS Reviews, 2023, 11, .	0.8	0